172 related articles for article (PubMed ID: 7961564)
1. The pharmacoeconomics of clozapine: a review.
Meltzer HY; Cola PA
J Clin Psychiatry; 1994 Sep; 55 Suppl B():161-5. PubMed ID: 7961564
[TBL] [Abstract][Full Text] [Related]
2. New vs. old antipsychotics: the Texas experience.
Reid WH
J Clin Psychiatry; 1999; 60 Suppl 1():23-5; discussion 28-30. PubMed ID: 10037167
[TBL] [Abstract][Full Text] [Related]
3. Pharmacoeconomic evaluation of treatments for refractory schizophrenia: clozapine-related studies.
Revicki DA
J Clin Psychiatry; 1999; 60 Suppl 1():7-11; discussion 28-30. PubMed ID: 10037164
[TBL] [Abstract][Full Text] [Related]
4. A randomized trial comparing clozapine and typical neuroleptic drugs in non-treatment-resistant schizophrenia.
Meltzer HY; Bobo WV; Lee MA; Cola P; Jayathilake K
Psychiatry Res; 2010 May; 177(3):286-93. PubMed ID: 20378185
[TBL] [Abstract][Full Text] [Related]
5. [Medico-economic evaluation of treatment with clozapine versus treatment with previous neuroleptics].
Geronimi-Ferret D; Lesay M; Barges-Bertocchio MH; Cornet-Bonnefont M; Robert H
Encephale; 1997 Sep; 23 Spec No 4():24-31. PubMed ID: 9417402
[TBL] [Abstract][Full Text] [Related]
6. A pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients.
Glazer WM; Ereshefsky L
J Clin Psychiatry; 1996 Aug; 57(8):337-45. PubMed ID: 8752015
[TBL] [Abstract][Full Text] [Related]
7. Pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: a cost-utility analysis.
Oh PI; Iskedjian M; Addis A; Lanctôt K; Einarson TR
Can J Clin Pharmacol; 2001; 8(4):199-206. PubMed ID: 11743592
[TBL] [Abstract][Full Text] [Related]
8. New drugs for the treatment of schizophrenia.
Meltzer HY
Psychiatr Clin North Am; 1993 Jun; 16(2):365-85. PubMed ID: 8101373
[TBL] [Abstract][Full Text] [Related]
9. Clozapine for refractory schizophrenia: the Illinois experience.
Buckman RW; Malan RD
J Clin Psychiatry; 1999; 60 Suppl 1():18-22; discussion 28-30. PubMed ID: 10037166
[TBL] [Abstract][Full Text] [Related]
10. Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.
Rosenheck R; Cramer J; Xu W; Grabowski J; Douyon R; Thomas J; Henderson W; Charney D
Health Serv Res; 1998 Dec; 33(5 Pt 1):1237-61. PubMed ID: 9865219
[TBL] [Abstract][Full Text] [Related]
11. Pharmacoeconomics of antipsychotic drug therapy.
Hargreaves WA; Shumway M
J Clin Psychiatry; 1996; 57 Suppl 9():66-76. PubMed ID: 8823354
[TBL] [Abstract][Full Text] [Related]
12. [Medico-economic study of Léponex (clozapine) in the Bordeaux Charles Perrens Hospital Center].
Bret P; Jolivel C; Bret MC; Veylit S; Martin C; Garcia P
Encephale; 1998; 24(4):365-77. PubMed ID: 9809242
[TBL] [Abstract][Full Text] [Related]
13. Effects of clozapine on cognitive function in schizophrenia.
Lee MA; Thompson PA; Meltzer HY
J Clin Psychiatry; 1994 Sep; 55 Suppl B():82-7. PubMed ID: 7961582
[TBL] [Abstract][Full Text] [Related]
14. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia.
Meltzer HY; Cola P; Way L; Thompson PA; Bastani B; Davies MA; Snitz B
Am J Psychiatry; 1993 Nov; 150(11):1630-8. PubMed ID: 8105705
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
[TBL] [Abstract][Full Text] [Related]
16. [The impact of antipsychotic medication on the incidence and the costs of inpatient treatment in people with schizophrenia: results from a prospective observational study].
Kilian R; Angermeyer MC
Psychiatr Prax; 2004 Apr; 31(3):138-46. PubMed ID: 15042477
[TBL] [Abstract][Full Text] [Related]
17. Generic replacement of clozapine: a simple decision model from a Canadian perspective.
Layton S; Barbeau M
Curr Med Res Opin; 2004 Apr; 20(4):453-9. PubMed ID: 15119982
[TBL] [Abstract][Full Text] [Related]
18. New antipsychotic agents: emerging clinical profiles.
Buckley PF
J Clin Psychiatry; 1999; 60 Suppl 1():12-7; discussion 28-30. PubMed ID: 10037165
[TBL] [Abstract][Full Text] [Related]
19. Should clozapine continue to be restricted to third-line status for schizophrenia?: a decision-analytic model.
Wang PS; Ganz DA; Benner JS; Glynn RJ; Avorn J
J Ment Health Policy Econ; 2004 Jun; 7(2):77-85. PubMed ID: 15208468
[TBL] [Abstract][Full Text] [Related]
20. Perspective and the measurement of costs and benefits for cost-effectiveness analysis in schizophrenia.
Meltzer D
J Clin Psychiatry; 1999; 60 Suppl 3():32-5; discussion 36-7. PubMed ID: 10073375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
